{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:34:45Z","timestamp":1792294485504,"version":"4.4.0"},"reference-count":270,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.autrev.2016.02.008","type":"journal-article","created":{"date-parts":[[2016,2,13]],"date-time":"2016-02-13T13:23:41Z","timestamp":1455369821000},"page":"513-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Cannabinoids and autoimmune diseases: A systematic review"],"prefix":"10.1016","volume":"15","author":[{"given":"Valeria","family":"Katchan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2016.02.008_bb0005","series-title":"Pharmacological actions of cannabinoids","first-page":"1","volume":"168","author":"Pertwee","year":"2005"},{"key":"10.1016\/j.autrev.2016.02.008_bb0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol Rev"},{"issue":"S1","key":"10.1016\/j.autrev.2016.02.008_bb0015","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1038\/sj.bjp.0706406","article-title":"Cannabinoid pharmacology: the first 66years","volume":"147","author":"Pertwee","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0020","article-title":"CB1 receptor antagonism: biological basis for metabolic effects","volume":"1\u201316","author":"Di Marzo","year":"2008","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.008_bb0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/er.2005-0009","article-title":"The emerging role of the endocannabinoid system in endocrine regulation and energy balance","volume":"27","author":"Pagotto","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.autrev.2016.02.008_bb0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/3-540-26573-2_2","article-title":"Cannabinoid receptor signaling","author":"Howlett","year":"2005","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0005-2760(98)00042-3","article-title":"\u2018Endocannabinoids\u2019and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance","volume":"1392","author":"Di Marzo","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.autrev.2016.02.008_bb0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3565(24)29345-9","article-title":"Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology","volume":"298","author":"Giuffrida","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.autrev.2016.02.008_bb0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0009-3084(02)00150-0","article-title":"A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation","volume":"121","author":"Dinh","year":"2002","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.autrev.2016.02.008_bb0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","article-title":"Pharmacology of cannabinoid CB1 and CB2 receptors","volume":"74","author":"Pertwee","year":"1997","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.autrev.2016.02.008_bb0055","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/sj.bjp.0703245","article-title":"O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties","volume":"129","author":"Pertwee","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0060","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/brain\/awg143","article-title":"Cannabis and the brain","volume":"126","author":"Iversen","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2016.02.008_bb0065","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.0022-3042.2001.00716.x","article-title":"Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1","volume":"80","author":"Marsicano","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.autrev.2016.02.008_bb0070","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.autrev.2016.02.008_bb0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/MOL.0b013e32803dbdec","article-title":"Endocannabinoids and the regulation of their levels in health and disease","volume":"18","author":"Di Marzo","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0080","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1073\/pnas.97.11.6155","article-title":"Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances","volume":"97","author":"Hwang","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2016.02.008_bb0085","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1046\/j.1460-9568.2003.02703.x","article-title":"Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro","volume":"17","author":"Ahluwalia","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.autrev.2016.02.008_bb0090","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/sj.bjp.0705711","article-title":"Modulation of trigeminal sensory neuron activity by the dual cannabinoidvanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide","volume":"141","author":"Price","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0095","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/22761","article-title":"Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide","volume":"400","author":"Zygmunt","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2016.02.008_bb0100","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1523\/JNEUROSCI.21-04-01104.2001","article-title":"Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation","volume":"21","author":"Tognetto","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.autrev.2016.02.008_bb0105","doi-asserted-by":"crossref","first-page":"10150","DOI":"10.1073\/pnas.152002699","article-title":"Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia","volume":"99","author":"Shin","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2016.02.008_bb0110","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/sj.bjp.0705643","article-title":"Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA)","volume":"141","author":"O'Sullivan","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0115","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nri1602","article-title":"Cannabinoid-based drugs as anti-inflammatory therapeutics","volume":"5","author":"Klein","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00109-011-0824-5","article-title":"Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system","volume":"90","author":"Lazzerini","year":"2012","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.autrev.2016.02.008_bb0125","series-title":"Inverse Agonism","first-page":"75","article-title":"Inverse agonism at cannabinoid receptors","author":"Pertwee","year":"2003"},{"key":"10.1016\/j.autrev.2016.02.008_bb0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1570159043476927","article-title":"Novel pharmacological targets for cannabinoids","volume":"2","author":"Pertwee","year":"2004","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0135","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0028-3908(98)00208-1","article-title":"Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors","volume":"38","author":"Cheer","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.autrev.2016.02.008_bb0140","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/sj.bjp.0704829","article-title":"Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site","volume":"137","author":"Barann","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0145","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1152\/jn.1995.73.2.907","article-title":"Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons","volume":"73","author":"Fan","year":"1995","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0150","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/sj.bjp.0705114","article-title":"Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold\u2013 Jarisch reflex","volume":"138","author":"Godlewski","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/syn.10121","article-title":"Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes","volume":"46","author":"Oz","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.autrev.2016.02.008_bb0160","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0006-8993(01)02825-6","article-title":"Interaction of anandamide with the M1 and M4 muscarinic acetylcholine receptors","volume":"915","author":"Christopoulos","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.autrev.2016.02.008_bb0165","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1023\/A:1020968922151","article-title":"In-vitro and in-vivo action of cannabinoids","volume":"24","author":"Akinshola","year":"1999","journal-title":"Neurochem Res"},{"key":"10.1016\/j.autrev.2016.02.008_bb0170","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s002109900078","article-title":"Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromo-cyclic AMP","volume":"360","author":"Akinshola","year":"1999","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0175","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ceca.2009.03.003","article-title":"Review role of endocannabinoids and endovanilloids in Ca2+ signaling","volume":"45","author":"De Petrocellis","year":"2009","journal-title":"Cell Calcium"},{"issue":"1\/2","key":"10.1016\/j.autrev.2016.02.008_bb0180","first-page":"14","article-title":"Pharmacology of cannabinoids","volume":"25","author":"Grotenhermen","year":"2004","journal-title":"Neuroendocrinol Lett"},{"key":"10.1016\/j.autrev.2016.02.008_bb0185","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0031-6997(25)06864-4","article-title":"Cannabinoid pharmacology","volume":"38","author":"Dewey","year":"1986","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.autrev.2016.02.008_bb0190","series-title":"Marijuana\/cannabinoids: neurobiology and neurophysiology","first-page":"165","article-title":"In vivo interactions between psychotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators","author":"Pertwee","year":"1992"},{"key":"10.1016\/j.autrev.2016.02.008_bb0195","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(03)00381-8","article-title":"The therapeutic potential of cannabis","volume":"2","author":"Baker","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0200","series-title":"Cannabinoids and the cholinergic system. Marihuana and medicine","first-page":"223","author":"Domino","year":"1999"},{"key":"10.1016\/j.autrev.2016.02.008_bb0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/chemse\/19.2.125","article-title":"Effects of cannabinoids (marijuana) on taste intensity and hedonic ratings and salivary flow of adults","volume":"19","author":"Mattes","year":"1994","journal-title":"Chem Senses"},{"key":"10.1016\/j.autrev.2016.02.008_bb0210","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1152\/jn.1995.73.2.907","article-title":"Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons","volume":"73","author":"Fan","year":"1995","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0215","series-title":"Pharmacology, toxicology, and therapeutic potential","first-page":"205","article-title":"Movement disorders. Cannabis and cannabinoids","author":"M\u00fcller-Vahl","year":"2002"},{"key":"10.1016\/j.autrev.2016.02.008_bb0220","series-title":"Pharmacology, toxicology, and therapeutic potential","first-page":"195","article-title":"Spastic disorders. Cannabis and cannabinoids","author":"Musty","year":"2002"},{"key":"10.1016\/j.autrev.2016.02.008_bb0225","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1517\/13543784.11.10.1365","article-title":"The therapeutic potential of the cannabinoids in neuroprotection","volume":"11","author":"Grundy","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2016.02.008_bb0230","series-title":"Pharmacology, toxicology, and therapeutic potential","first-page":"101","article-title":"Cannabinoids as neuroprotectants against ischemia. Cannabis and cannabinoids","author":"A.","year":"2002"},{"key":"10.1016\/j.autrev.2016.02.008_bb0235","series-title":"Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential","first-page":"389","article-title":"HU-211: Cannabinoid Neuroprotective Agent","author":"Mechoulam","year":"2002"},{"key":"10.1016\/j.autrev.2016.02.008_bb0240","series-title":"Marihuana and medicine","first-page":"245","article-title":"The psychologic and physiologic effects of active cannabinoids","author":"Perez-Reyes","year":"1999"},{"key":"10.1016\/j.autrev.2016.02.008_bb0245","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.72.1.20","article-title":"Shortterm effects of smoked marihuana on left ventricular function in man","volume":"72","author":"Tashkin","year":"1977","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2016.02.008_bb0250","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cpt1975183287","article-title":"Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion","volume":"18","author":"Benowitz","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2016.02.008_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)06862-0","article-title":"Health aspects of cannabis","volume":"38","author":"Hollister","year":"1986","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.autrev.2016.02.008_bb0260","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s001090050287","article-title":"Cardiovascular actions of cannabinoids and their generation during shock","volume":"76","author":"Wagner","year":"1998","journal-title":"J Mol Med"},{"key":"10.1016\/j.autrev.2016.02.008_bb0265","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0014-2999(01)01112-8","article-title":"Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors","volume":"423","author":"Wagner","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0270","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0022-3565(24)36714-X","article-title":"Cannabinoid induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors","volume":"281","author":"Lake","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.autrev.2016.02.008_bb0275","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/35071088","article-title":"Leptin-regulated endocannabinoids are involved in maintaining food intake","volume":"410","author":"Di Marzo","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2016.02.008_bb0280","series-title":"First European Workshop on Cannabinoid Research. Madrid (Spain)","article-title":"The ubiquitous role of endocannabinoids in physiological processes: examples in neuroprotection, feeding and bone formation","author":"Mechoulam","year":"2003"},{"key":"10.1016\/j.autrev.2016.02.008_bb0285","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0022-3565(25)23416-4","article-title":"Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents","volume":"249","author":"Shook","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.autrev.2016.02.008_bb0290","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2036.1999.00441.x","article-title":"Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study","volume":"13","author":"McCallum","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2016.02.008_bb0295","series-title":"Pharmacology, toxicology, and therapeutic potential","first-page":"289","article-title":"Hormonal system and reproduction. Cannabis and cannabinoids","author":"Murphy","year":"2002"},{"key":"10.1016\/j.autrev.2016.02.008_bb0300","series-title":"Pharmacology, toxicology, and therapeutic potential","first-page":"215","article-title":"Glaucoma and cannabinoids. Cannabis and cannabinoids","author":"Pate","year":"2002"},{"key":"10.1016\/j.autrev.2016.02.008_bb0305","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0024-3205(02)02339-1","article-title":"Topically administered CB(2)-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive rabbits","volume":"72","author":"Laine","year":"2003","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.008_bb0310","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00213-009-1517-4","article-title":"Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers","volume":"205","author":"Horder","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.autrev.2016.02.008_bb0315","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00008877-199905000-00009","article-title":"SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats","volume":"10","author":"Costa","year":"1999","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0320","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s002130050326","article-title":"Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors","volume":"132","author":"Arnone","year":"1997","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0325","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0024-3205(98)00322-1","article-title":"Appetite suppression and weight loss after the cannabinoid antagonist SR 141716","volume":"63","author":"Colombo","year":"1998","journal-title":"Life Sci"},{"key":"10.1016\/j.autrev.2016.02.008_bb0330","first-page":"179","article-title":"SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset","volume":"9","author":"Simiand","year":"1998","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0335","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0163-7258(02)00257-7","article-title":"Tetrahydrocannabinol and endocannabinoids in feeding and appetite","volume":"95","author":"Berry","year":"2002","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.autrev.2016.02.008_bb0340","first-page":"267","article-title":"Cannabinoids in chronic pain and palliative care","volume":"58","author":"Bonf\u00e1","year":"2008","journal-title":"Rev Bras Anestesiol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0345","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1189\/jlb.0303101","article-title":"The cannabinoid system and immune modulation","volume":"74","author":"Klein","year":"2003","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0350","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0009-3084(00)00195-X","article-title":"Cannabinoid receptors and the regulation of immune response","volume":"108","author":"Berdyshev","year":"2000","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.autrev.2016.02.008_bb0355","doi-asserted-by":"crossref","DOI":"10.1007\/3-540-26573-2_13","article-title":"Effects on the immune system","volume":"385\u2013423","author":"Cabral","year":"2005","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0360","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0005-2760(98)00110-6","article-title":"Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system","volume":"1394","author":"Pestonjamasp","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.autrev.2016.02.008_bb0365","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1074\/jbc.272.6.3315","article-title":"Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes","volume":"272","author":"Bisogno","year":"1997","journal-title":"J Biol Chem"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2016.02.008_bb0370","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0014-2999(01)01122-0","article-title":"Differential expression of cannabinoid cb(2) receptor mrna in mouse immune cell subpopulations and following b cell stimulation","volume":"423","author":"Lee","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0375","first-page":"47","article-title":"Endocannabinoids and the gastrointestinal tract","volume":"29","author":"Massa","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.autrev.2016.02.008_bb0380","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1126\/science.1142265","article-title":"Attenuation of allergic contact dermatitis through the endocannabinoid system","volume":"316","author":"Karsak","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.autrev.2016.02.008_bb0385","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s00109-005-0698-5","article-title":"The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract","volume":"83","author":"Massa","year":"2005","journal-title":"J Mol Med"},{"key":"10.1016\/j.autrev.2016.02.008_bb0390","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1365-2044.2001.02269.x","article-title":"Pharmacological actions and therapeutic uses of cannabis and cannabinoids","volume":"56","author":"Kumar","year":"2001","journal-title":"Anaesthesia"},{"key":"10.1016\/j.autrev.2016.02.008_bb0395","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1189\/jlb.0303101","article-title":"The cannabinoid system and immune modulation","volume":"74","author":"Klein","year":"2003","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0400","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0009-3084(00)00195-X","article-title":"Cannabinoid receptors and the regulation of immune response","volume":"108","author":"Berdyshev","year":"2000","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.autrev.2016.02.008_bb0405","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1128\/iai.62.9.4015-4020.1994","article-title":"Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection","volume":"62","author":"Newton","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.autrev.2016.02.008_bb0410","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.4049\/jimmunol.164.12.6461","article-title":"Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-g, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection","volume":"164","author":"Klein","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0415","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4049\/jimmunol.165.1.373","article-title":"Delta-9-tetrahydrocan-nabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway","volume":"165","author":"Zhu","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0420","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0165-5728(02)00370-3","article-title":"Delta 9-tetrahydrocannabinol regulates Th1\/Th2 cytokine balance in activated human T-cells","volume":"133","author":"Yuan","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0425","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2016.02.008_bb0430","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-3565(24)37365-3","article-title":"Comparative receptor binding analyses of cannabinoid agonists and antagonists","volume":"285","author":"Thomas","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.autrev.2016.02.008_bb0435","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000137430","article-title":"Chronic administration of cannabidiol to healthy volunteers and epileptic patients","volume":"21","author":"Cunha","year":"1980","journal-title":"Pharmacology"},{"key":"10.1016\/j.autrev.2016.02.008_bb0440","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington's disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"issue":"8","key":"10.1016\/j.autrev.2016.02.008_bb0445","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.imbio.2009.04.001","article-title":"Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression","volume":"215","author":"Rieder","year":"2010","journal-title":"Immunobiology"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.008_bb0450","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0165-5728(94)90152-X","article-title":"Anandamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis","volume":"55","author":"Schwarz","year":"1994","journal-title":"J Neuroimmunol"},{"issue":"41","key":"10.1016\/j.autrev.2016.02.008_bb0455","doi-asserted-by":"crossref","first-page":"31938","DOI":"10.1074\/jbc.M005722200","article-title":"Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors","volume":"275","author":"Maccarrone","year":"2000","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.autrev.2016.02.008_bb0460","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0022-3565(24)37693-1","article-title":"Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of bcl-2 and caspase-1","volume":"286","author":"Zhu","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.autrev.2016.02.008_bb0465","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1124\/jpet.102.033506","article-title":"Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo","volume":"302","author":"McKallip","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.autrev.2016.02.008_bb0470","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.intimp.2008.01.018","article-title":"A comparative study on cannabidiol-induced apoptosis in murine thymocytes and el-4 thymoma cells","volume":"8","author":"Lee","year":"2008","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.autrev.2016.02.008_bb0475","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3181\/00379727-209-43897b","article-title":"Delta 9-tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila","volume":"209","author":"Klein","year":"1995","journal-title":"Proc Soc Exp Biol Med"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2016.02.008_bb0480","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0014-5793(95)00746-V","article-title":"Cannabinoids enhance human b-cell growth at low nanomolar concentrations","volume":"369","author":"Derocq","year":"1995","journal-title":"FEBS Lett"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2016.02.008_bb0485","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0014-5793(95)00746-V","article-title":"Cannabinoids enhance human b-cell growth at low nanomolar concentrations","volume":"369","author":"Derocq","year":"1995","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/j.autrev.2016.02.008_bb0490","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0024-3205(92)90009-E","article-title":"Delta 9-tetrahydrocannabinol suppresses concanavalin A induced increase in cytoplasmic free calcium in mouse thymocytes","volume":"51","author":"Yebra","year":"1992","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.autrev.2016.02.008_bb0495","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/08916930500356674","article-title":"Cannabidiol lowers incidence of diabetes in non-obese diabetic mice","volume":"39","author":"Weiss","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2016.02.008_bb0500","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4684-5925-8_7","article-title":"Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro","volume":"288","author":"Watzl","year":"1991","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0505","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/02791072.1992.10471635","article-title":"Marijuana and immunity","volume":"24","author":"Hollister","year":"1992","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.autrev.2016.02.008_bb0510","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/jcb.10291","article-title":"Prospects for cannabinoids as anti-inflammatory agents","volume":"88","author":"Zurier","year":"2003","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.autrev.2016.02.008_bb0515","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0165-5728(97)00227-0","article-title":"Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease","volume":"83","author":"Cabral","year":"1998","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.008_bb0520","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2826.2008.01674.x","article-title":"Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation","volume":"20","author":"De Filippis","year":"2008","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0525","doi-asserted-by":"crossref","first-page":"H1145","DOI":"10.1152\/ajpheart.01328.2007","article-title":"CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways","volume":"294","author":"Montecucco","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0530","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0009-3084(02)00159-7","article-title":"Effects of delta-9-tetrahydrocannabinol on human immune function and host defense","volume":"121","author":"Roth","year":"2002","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.autrev.2016.02.008_bb0535","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11481-005-9007-x","article-title":"Cannabinoid-induced immune suppression and modulation of antigen-presenting cells","volume":"1","author":"Klein","year":"2006","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0540","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1124\/jpet.109.163055","article-title":"Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor","volume":"333","author":"Raborn","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.autrev.2016.02.008_bb0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2008.05.002","article-title":"Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation","volume":"595","author":"Patinkin","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0550","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11481-007-9077-z","article-title":"The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES\/CCL5: linkage to the CB2 receptor","volume":"3","author":"Raborn","year":"2008","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0555","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.bjp.0707523","article-title":"CB2 receptor-mediated migration of immune cells: it can go either way","volume":"153","author":"Miller","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0560","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1523\/JNEUROSCI.23-04-01398.2003","article-title":"Nonpsychotropic cannabinoid receptors regulate microglial cell migration","volume":"23","author":"Walter","year":"2003","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.autrev.2016.02.008_bb0565","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10787-012-0133-9","article-title":"Differential migratory properties of monocytes isolated from human subjects na\u00efve and non-na\u00efve to cannabis","volume":"21","author":"Sexton","year":"2013","journal-title":"Inflammopharmacology"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.008_bb0570","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1124\/jpet.106.108381","article-title":"Cannabinoid treatment suppresses the t-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection","volume":"319","author":"Lu","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.008_bb0575","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1124\/mol.108.047035","article-title":"Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory t cells","volume":"74","author":"Hegde","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0580","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1191\/0960327104ht426oa","article-title":"Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students","volume":"23","author":"El-Gohary","year":"2004","journal-title":"Hum Exp Toxicol"},{"issue":"4","key":"10.1016\/j.autrev.2016.02.008_bb0585","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0091-6749(76)90192-5","article-title":"Intact humoral and cell-mediated immunity in chronic marijuana smoking","volume":"58","author":"Rachelefsky","year":"1976","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0590","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1567-5769(01)00147-3","article-title":"Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation","volume":"2","author":"Carlisle","year":"2002","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0595","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.bjp.0706215","article-title":"Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1\/2 kinase signaling","volume":"145","author":"Correa","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0600","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1016\/j.febslet.2005.10.030","article-title":"2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes","volume":"579","author":"Gokoh","year":"2005","journal-title":"FEBS Lett"},{"key":"10.1016\/j.autrev.2016.02.008_bb0605","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1471-4159.2005.03380.x","article-title":"Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli","volume":"95","author":"Maresz","year":"2005","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.autrev.2016.02.008_bb0610","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/15287398909531243","article-title":"Delta-9-tetrahydrocannabinol inhibits macrophage protein expression in response to bacterial immunomodulators","volume":"26","author":"Cabral","year":"1989","journal-title":"J Toxicol Environ Health"},{"issue":"6","key":"10.1016\/j.autrev.2016.02.008_bb0615","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/jlb.39.6.679","article-title":"Tetrahydrocannabinol-induced suppression of macrophage spreading and phagocytic activity in vitro","volume":"39","author":"Lopez-Cepero","year":"1986","journal-title":"J Leukoc Biol"},{"issue":"3","key":"10.1016\/j.autrev.2016.02.008_bb0620","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0022-3565(25)09609-0","article-title":"Delta 9-tetrahydrocannabinol modulates antigen processing by macrophages","volume":"273","author":"McCoy","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.autrev.2016.02.008_bb0625","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/jlb.50.2.192","article-title":"Selective inhibition of natural killer but not natural cytotoxic activity in a cloned cell line by delta-9-tetrahydrocannabinol","volume":"50","author":"Wang","year":"1991","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0630","first-page":"97","article-title":"Suppressive effect of tetrahydrocannabinol on specific T cell subpopulations in the thymus","volume":"19","author":"Pross","year":"1992","journal-title":"Thymus"},{"key":"10.1016\/j.autrev.2016.02.008_bb0635","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3181\/00379727-200-43452","article-title":"Delta 9-tetrahydrocannabinol decreases cytotoxic T lymphocyte activity to herpes simplex virus type 1-infected cells","volume":"200","author":"Fischer-Stenger","year":"1992","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.autrev.2016.02.008_bb0640","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.4049\/jimmunol.170.10.4953","article-title":"Differential roles of CB1 and CB2 cannabinoid receptors in mast cells","volume":"170","author":"Samson","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0645","first-page":"25","article-title":"Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells","volume":"25","author":"Small-Howard","year":"2005","journal-title":"Biochem J"},{"key":"10.1016\/j.autrev.2016.02.008_bb0650","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.lfs.2006.09.026","article-title":"Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice","volume":"80","author":"Ueda","year":"2007","journal-title":"Life Sci"},{"issue":"Pt10","key":"10.1016\/j.autrev.2016.02.008_bb0655","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/brain\/awg224","article-title":"Cannabinoids inhibit neurodegeneration in models of multiple sclerosis","volume":"126","author":"Pryce","year":"2003","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.autrev.2016.02.008_bb0660","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1254\/jphs.FMJ04003X2","article-title":"New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application","volume":"96","author":"Fujiwara","year":"2004","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.008_bb0665","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.neuroscience.2005.02.045","article-title":"Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation","volume":"134","author":"Jackson","year":"2005","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.autrev.2016.02.008_bb0670","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.bjp.0707003","article-title":"Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors","volume":"150","author":"Pryce","year":"2007","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.autrev.2016.02.008_bb0675","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.nbd.2005.03.002","article-title":"Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and\/or vanilloid receptors in a rat model of multiple sclerosis","volume":"20","author":"Cabranes","year":"2005","journal-title":"J Neurobiol Dis"},{"issue":"7","key":"10.1016\/j.autrev.2016.02.008_bb0680","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1523\/JNEUROSCI.23-07-02511.2003","article-title":"Therapeutic action of cannabinoids in a murine model of multiple sclerosis","volume":"23","author":"Arevalo-Martin","year":"2003","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.008_bb0685","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neuron.2005.11.027","article-title":"The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells","volume":"49","author":"Eljaschewitsch","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.autrev.2016.02.008_bb0690","doi-asserted-by":"crossref","DOI":"10.3310\/hta19120","article-title":"The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis","volume":"19","author":"Ball","year":"2015","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.autrev.2016.02.008_bb0695","doi-asserted-by":"crossref","unstructured":"Notcutt LW, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex\u00ae (nabiximols). Eur J Pain. May 2009 Mult Scler. 2012 Feb;18(2):219\u201328","DOI":"10.1177\/1352458511419700"},{"issue":"5","key":"10.1016\/j.autrev.2016.02.008_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpain.2008.05.014","article-title":"Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis","volume":"13","author":"Conte","year":"2009","journal-title":"Eur J Pain"},{"issue":"3","key":"10.1016\/j.autrev.2016.02.008_bb0705","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","article-title":"Sativex spasticity in MS Study Group. randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis","volume":"14","author":"Collin","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0710","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/BOR.0b013e328349c2b1","article-title":"Inflammation in osteoarthritis","volume":"23","author":"Goldring","year":"2011","journal-title":"Curr Rheumatol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0715","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/art.20050","article-title":"A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis","volume":"50","author":"Sumariwalla","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.02.008_bb0720","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/1529-0131(199801)41:1<163::AID-ART20>3.0.CO;2-9","article-title":"Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure","volume":"41","author":"Zurier","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.02.008_bb0725","doi-asserted-by":"crossref","first-page":"9561","DOI":"10.1073\/pnas.160105897","article-title":"The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis","volume":"97","author":"Malfait","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2016.02.008_bb0730","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-2952(02)01604-0","article-title":"Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid","volume":"65","author":"Zurier","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0735","first-page":"574","article-title":"Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes","volume":"26","author":"Selvi","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0740","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/jcb.21046","article-title":"Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid","volume":"100","author":"Johnson","year":"2007","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.autrev.2016.02.008_bb0745","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1211\/jpp.58.3.0009","article-title":"Arthritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1alphainduced matrix degradation in bovine articular chondrocytes in-vitro","volume":"58","author":"Mbvundula","year":"2006","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0750","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"Cannabinoid receptors and their ligands: beyond CB and CB","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.autrev.2016.02.008_bb0755","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1042\/BST0341095","article-title":"Cannabinoids and PPARalpha signalling","volume":"34","author":"Sun","year":"2006","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.autrev.2016.02.008_bb0760","doi-asserted-by":"crossref","first-page":"611e6","DOI":"10.1016\/j.imbio.2009.09.007","article-title":"Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease","volume":"215","author":"O'Sullivan","year":"2010","journal-title":"Immunobiology"},{"issue":"3","key":"10.1016\/j.autrev.2016.02.008_bb0765","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/art.20050","article-title":"Ester; a novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis","volume":"50","author":"Sumariwalla,","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.02.008_bb0770","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nn1916","article-title":"Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors","volume":"10","author":"Agarwal","year":"2007","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.autrev.2016.02.008_bb0775","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1533-2500.2010.00401.x","article-title":"A double-blind, randomized, placebocontrolled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee","volume":"11","author":"Chappell","year":"2001","journal-title":"Pain Pract"},{"key":"10.1016\/j.autrev.2016.02.008_bb0780","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/sj.bjp.0703919","article-title":"Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones","volume":"132","author":"Millns","year":"2001","journal-title":"Brit J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0785","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.pain.2008.06.007","article-title":"Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons","volume":"138","author":"Anand","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.autrev.2016.02.008_bb0790","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/26481","article-title":"An analgesia circuit activated by cannabinoids","volume":"395","author":"Meng","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2016.02.008_bb0795","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/art.23156","article-title":"Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees","volume":"58","author":"Schuelert","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.02.008_bb0800","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar2401","article-title":"Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis","volume":"10","author":"Richardson","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2016.02.008_bb0805","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/art.27698","article-title":"Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain","volume":"62","author":"Sagar","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.008_bb0810","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/kei183","article-title":"Preliminary assessment of the efficacy, tolerability and safety of a cannabis based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis","volume":"45","author":"Blake","year":"2006","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.autrev.2016.02.008_bb0815","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1365-2125.2011.03970.x","article-title":"Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials","volume":"72","author":"Lynch","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0820","first-page":"356","article-title":"Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review","volume":"22","author":"Dziadzio","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0825","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/1523-1747.ep12483971","article-title":"Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6","volume":"97","author":"Duncan","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0830","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cellsig.2004.05.011","article-title":"Cannabinoids down-regulate PI3K\/akt and Erk signalling pathways and activate proapoptotic function of bad protein","volume":"17","author":"Ellert-Miklaszewska","year":"2005","journal-title":"Cell Signal"},{"key":"10.1016\/j.autrev.2016.02.008_bb0835","unstructured":"Garcia-Gonzalez E, Galeazzi M; Selvi, E. Are cannabinoids able to modulate fibrotic progression in systemic sclerosis? Autoimmunity Reviews 2016, (in press)."},{"key":"10.1016\/j.autrev.2016.02.008_bb0840","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nri1602","article-title":"Cannabinoid-based drugs as anti-inflammatory therapeutics","volume":"5","author":"Klein","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0845","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00109-011-0824-5","article-title":"Adenosine A2A receptor activation stimulates Collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system","volume":"90","author":"Lazzerini","year":"2012","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.autrev.2016.02.008_bb0850","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","article-title":"Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis","volume":"71","author":"Gonzalez","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2016.02.008_bb0855","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/9442","article-title":"The NOD mouse model of type 1 diabetes: as good as it gets?","volume":"5","author":"Atkinson","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2016.02.008_bb0860","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1196\/annals.1288.005","article-title":"Beta cell death and protection","volume":"1005","author":"Mandrup-Poulsen","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2016.02.008_bb0865","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-3-642-17214-4_4","article-title":"Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes","volume":"203","author":"Di Marzo","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0870","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.neuropharm.2007.06.029","article-title":"Cannabidiol arrests onset of autoimmune diabetes in NOD mice","volume":"54","author":"Weiss","year":"2008","journal-title":"Neuropharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0875","first-page":"528","article-title":"Current concept of the pathogenesis of autoimmune type 1 diabetes mellitus","volume":"57","author":"Satoh","year":"1999","journal-title":"Nippon Rinsho"},{"key":"10.1016\/j.autrev.2016.02.008_bb0880","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0960-9822(95)00170-9","article-title":"T-cell subsets. Who does the polarizing?","volume":"5","author":"Swain","year":"1995","journal-title":"Curr Biol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0885","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/diabetes.48.1.34","article-title":"Absolute requirement of macrophages for the development and activation of beta-cell cytotoxic CD8+T-cells in T-cell receptor transgenic NOD mice","volume":"48","author":"Jun","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2016.02.008_bb0890","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0895","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4049\/jimmunol.156.3.1196","article-title":"Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines","volume":"156","author":"Skeen","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0900","first-page":"1072","article-title":"In vitro production of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in insulin-dependent diabetes mellitus","volume":"77","author":"Ohno","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"0","key":"10.1016\/j.autrev.2016.02.008_bb0905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000356512","article-title":"Cannabis finds its way into treatment of Crohn's disease","volume":"93","author":"Schicho","year":"2014","journal-title":"Pharmacology"},{"key":"10.1016\/j.autrev.2016.02.008_bb0910","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0016-5085(03)00892-8","article-title":"An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice","volume":"125","author":"Izzo","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2016.02.008_bb0915","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI200419465","article-title":"The endogenous cannabinoid system protects against colonic inflammation","volume":"113","author":"Massa","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2016.02.008_bb0920","first-page":"89","article-title":"Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis","volume":"61","author":"Engel","year":"2010","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0925","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00109-009-0512-x","article-title":"Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis","volume":"87","author":"Borrelli","year":"2009","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.autrev.2016.02.008_bb0930","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000336871","article-title":"Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice","volume":"89","author":"Schicho","year":"2012","journal-title":"Pharmacology"},{"key":"10.1016\/j.autrev.2016.02.008_bb0935","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1476-5381.2010.00791.x","article-title":"The effects of delta-tetrahydrocan-nabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis","volume":"160","author":"Jamontt","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0940","doi-asserted-by":"crossref","first-page":"G364","DOI":"10.1152\/ajpgi.00407.2005","article-title":"Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium","volume":"291","author":"Kimball","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.autrev.2016.02.008_bb0945","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1096\/fj.10-176602","article-title":"Increasing endogenous 2-ara-chidonoylglycerol levels counteracts colitis and related systemic inflammation","volume":"25","author":"Alhouayek","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.autrev.2016.02.008_bb0950","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/mi.2011.18","article-title":"The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease","volume":"4","author":"Di Sabatino","year":"2011","journal-title":"Mucosal Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.008_bb0955","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/13543784.12.1.39","article-title":"Cannabinoids for gastrointestinal diseases: potential therapeutic applications","volume":"12","author":"Di Carlo","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2016.02.008_bb0960","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/aws136","article-title":"Effect of long-term cannabis use on axonal fiber connectivity","volume":"135","author":"Zalesky","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2016.02.008_bb0965","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1371\/journal.pone.0006893","article-title":"Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue","volume":"4","author":"Marqu\u00e9z","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2016.02.008_bb0970","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.gastro.2005.05.026","article-title":"Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing","volume":"129","author":"Wright","year":"2005","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.autrev.2016.02.008_bb0975","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.taap.2011.11.005","article-title":"Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-\/-) mice by attenuating the activation of T cells and promoting their apoptosis","volume":"258","author":"Singh","year":"2012","journal-title":"Toxicol Appl Pharmacol."},{"key":"10.1016\/j.autrev.2016.02.008_bb0980","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pharmthera.2009.12.005","article-title":"Cannabinoids and the gut: new developments and emerging concepts","volume":"126","author":"Izzo","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.autrev.2016.02.008_bb0985","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.molmed.2012.07.009","article-title":"The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity","volume":"18","author":"Alhouayek","year":"2012","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.autrev.2016.02.008_bb0990","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1136\/gut.2008.148791","article-title":"Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects","volume":"57","author":"Izzo","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2016.02.008_bb0995","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1124\/jpet.110.169946","article-title":"Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl) methanone (SAB378), a peripherally restricted cannabinoid CB1\/CB2 receptors agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice","volume":"334","author":"Cluny","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.autrev.2016.02.008_bb1000","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cgh.2013.04.034","article-title":"Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study","volume":"11","author":"Naftali","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.autrev.2016.02.008_bb1005","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/MEG.0b013e328349bb4c","article-title":"Cannabis use amongst patients with inflammatory bowel disease","volume":"23","author":"Lal","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2016.02.008_bb1010","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000358155","article-title":"Cannabis for inflammatory bowel disease","volume":"32","author":"Naftali","year":"2014","journal-title":"Dig Dis"},{"key":"10.1016\/j.autrev.2016.02.008_bb1015","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/0016-5085(85)90007-1","article-title":"Recurrence after surgery in Crohn's disease. relationship to location of disease (clinical pattern) and surgical indication","volume":"88","author":"Whelan","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2016.02.008_bb1020","first-page":"455","article-title":"Treatment of Crohn's disease with cannabis: an observational study","volume":"13","author":"Naftali","year":"2011","journal-title":"IMAJ"},{"key":"10.1016\/j.autrev.2016.02.008_bb1025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(03)00381-8","article-title":"The therapeutic potential of cannabis","volume":"2","author":"Baker","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2016.02.008_bb1030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000332079","article-title":"Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study","volume":"85","author":"Lahat","year":"2012","journal-title":"Digestion"},{"issue":"2","key":"10.1016\/j.autrev.2016.02.008_bb1035","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpain.2012.10.009","article-title":"Low dose vaporized cannabis significantly improves neuropathic pain","volume":"14","author":"Wilsey","year":"2013","journal-title":"J Pain"},{"key":"10.1016\/j.autrev.2016.02.008_bb1040","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","article-title":"Recommendations for the pharmacological management of neuropathic pain: an overview and literature update","volume":"85","author":"Dworkin","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2016.02.008_bb1045","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.nurt.2009.08.002","article-title":"Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside","volume":"6","author":"Rahn","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.autrev.2016.02.008_bb1050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1155\/2011\/654651","article-title":"The need for a Canadian pain strategy","volume":"16","author":"Lynch","year":"2011","journal-title":"Pain Res Manag"},{"key":"10.1016\/j.autrev.2016.02.008_bb1055","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1017\/S0033291705006859","article-title":"Suicidality in chronic pain: review of the prevalence, risk factors and psychological links","volume":"36","author":"Tang","year":"2006","journal-title":"Psychol Med"},{"key":"10.1016\/j.autrev.2016.02.008_bb1060","doi-asserted-by":"crossref","unstructured":"Lynch M, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 72:5: 735\u2013744.","DOI":"10.1111\/j.1365-2125.2011.03970.x"},{"key":"10.1016\/j.autrev.2016.02.008_bb1065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.323.7303.13","article-title":"Are cannabinoids an effective and safe treatment option in the management of pain?","volume":"323","author":"Campbell","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2016.02.008_bb1070","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2174\/1381612003399473","article-title":"Ajulemic acid (CT3): a potent analog of the acid metabolites of THC","volume":"6","author":"Burstein","year":"2000","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.autrev.2016.02.008_bb1075","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1124\/mol.63.5.983","article-title":"Activation and binding of peroxisome proliferator-activated receptor \u03b3 by synthetic cannabinoid ajulemic acid","volume":"63","author":"Liu","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb1080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0024-3205(98)00256-2","article-title":"Analgesic effects of 1\u2032,1'dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice","volume":"63","author":"Burstein","year":"1998","journal-title":"Life Sci"},{"key":"10.1016\/j.autrev.2016.02.008_bb1085","first-page":"1757","article-title":"Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain","volume":"290(13)","author":"Karst","year":"2003"},{"key":"10.1016\/j.autrev.2016.02.008_bb1090","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/01.wnl.0000253187.66183.9c","article-title":"Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial","volume":"68","author":"Abrams","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2016.02.008_bb1095","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/npp.2008.120","article-title":"Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial","volume":"34","author":"Ellis","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.autrev.2016.02.008_bb1100","first-page":"1","article-title":"Painful HIV-associated sensory neuropathy","volume":"XVIII","author":"Phillips","year":"2010"},{"key":"10.1016\/j.autrev.2016.02.008_bb1105","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/01.anes.0000286986.92475.b7","article-title":"Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers","volume":"107","author":"Wallace","year":"2007","journal-title":"Anesthesiology"},{"issue":"14","key":"10.1016\/j.autrev.2016.02.008_bb1110","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.091414","article-title":"Smoked cannabis for chronic neuropathic pain: a randomized controlled trial","volume":"182","author":"Ware","year":"2010","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.008_bb1115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-857X(21)00029-6","article-title":"Fibromyalgia: the clinical syndrome","volume":"15","author":"Wolfe","year":"1989","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"10.1016\/j.autrev.2016.02.008_bb1120","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jpsychores.2015.10.004","article-title":"Common and unique associated factors for medically unexplained chronic widespread pain and chronic fatigue","volume":"79","author":"McBeth","year":"2011","journal-title":"J Psychosom Res"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.008_bb1125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12026-011-8210-5","article-title":"Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease","volume":"51","author":"5Z","year":"2011","journal-title":"Immunologic Research"},{"issue":"3","key":"10.1016\/j.autrev.2016.02.008_bb1130","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1212\/WNL.46.3.593","article-title":"Problems with myofascial pain syndrome and fibromyalgia syndrome","volume":"46","author":"Bohr","year":"1996","journal-title":"Neurology"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2016.02.008_bb1135","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1016\/S0014-2999(96)00952-1","article-title":"SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice","volume":"319","author":"Richardson","year":"1997","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.autrev.2016.02.008_bb1140","doi-asserted-by":"crossref","first-page":"18440","DOI":"10.1371\/journal.pone.0018440","article-title":"Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life","volume":"6","author":"Fiz","year":"2011","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.autrev.2016.02.008_bb1145","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1213\/ANE.0b013e3181c76f70","article-title":"The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial","volume":"110","author":"Ware","year":"2010","journal-title":"Anesth Analg"},{"issue":"13","key":"10.1016\/j.autrev.2016.02.008_bb1150","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1503\/cmaj.071178","article-title":"Adverse effects of medical cannabinoids: a systematic review","volume":"178","author":"Wang","year":"2008","journal-title":"Can Med Assoc J"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2016.02.008_bb1155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/j.1552-4604.1975.tb02348.x","article-title":"Analgesic effect of delta-9-tetrahydrocannabinol","volume":"15","author":"Noyes","year":"1975","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb1160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/cpt197518184","article-title":"The analgesic properties of delta-9-tetrahydrocannabinol and codeine","volume":"18","author":"Noyes","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2016.02.008_bb1165","doi-asserted-by":"crossref","first-page":"320S","DOI":"10.1002\/j.1552-4604.1981.tb02610.x","article-title":"Evaluation of intramuscular levonantradol and plecebo in acute postoperative pain","volume":"21","author":"Jain","year":"1981","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb1170","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/1097-0142(19810401)47:7<1746::AID-CNCR2820470704>3.0.CO;2-4","article-title":"A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy","volume":"47","author":"Chang","year":"1981","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.autrev.2016.02.008_bb1175","first-page":"525","article-title":"Inhalation marijuana as an antiemetic for cancer chemotherapy","volume":"88","author":"Vinciguerra","year":"1988","journal-title":"N Y State J Med"},{"key":"10.1016\/j.autrev.2016.02.008_bb1180","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/archinte.1980.00330220019010","article-title":"Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis","volume":"140","author":"Orr","year":"1980","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.autrev.2016.02.008_bb1185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJM198001173020302","article-title":"Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine","volume":"302","author":"Sallan","year":"1980","journal-title":"N Engl J Med"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2016.02.008_bb1190","first-page":"219","article-title":"Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis","volume":"64","author":"Steele","year":"1980","journal-title":"Cancer Treat Rep"},{"issue":"6","key":"10.1016\/j.autrev.2016.02.008_bb1195","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/00000421-198512000-00014","article-title":"Phase 1 trial of levonantradol in chemotherapy-induced emesis","volume":"8","author":"Tyson","year":"1985","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.autrev.2016.02.008_bb1200","first-page":"13","article-title":"Management of anorexia-cachexia associated with cancer and HIV infection","volume":"5","author":"Gorter","year":"1991","journal-title":"Oncol Suppl"},{"issue":"7\u20138","key":"10.1016\/j.autrev.2016.02.008_bb1205","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/106002809302700701","article-title":"Effect of dronabinol on nutritional status in HIV infection","volume":"27","author":"Struwe","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.autrev.2016.02.008_bb1210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0885-3924(94)00117-4","article-title":"Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS","volume":"10","author":"Beal","year":"1995","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.autrev.2016.02.008_bb1215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0885-3924(97)00038-9","article-title":"Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia","volume":"14","author":"Beal","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.autrev.2016.02.008_bb1220","article-title":"The medical value of marijuana and related substances. Marijuana and Medicine","author":"National Academy of Science, Institute of Medicine","year":"1999"},{"issue":"1","key":"10.1016\/j.autrev.2016.02.008_bb1225","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1300\/J251v07n01_04","article-title":"Delta-9-THC in the treatment of spasticity associated with multiple sclerosis","volume":"7","author":"Ungerleider","year":"1987","journal-title":"Adv Alcohol Subst Abuse"},{"issue":"4","key":"10.1016\/j.autrev.2016.02.008_bb1230","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458504ms1063oa","article-title":"An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis","volume":"10","author":"Brady","year":"2004","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.autrev.2016.02.008_bb1235","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nm0704-678","article-title":"Cannabinoids cool the intestine","volume":"10","author":"Kunos","year":"2004","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.autrev.2016.02.008_bb1240","first-page":"267","article-title":"Cannabinoids in chronic pain and palliative care","volume":"58","author":"Bonf\u00e1","year":"2008","journal-title":"Rev Bras Anestesiol"},{"key":"10.1016\/j.autrev.2016.02.008_bb1245","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0014-2999(01)00798-1","article-title":"Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain","volume":"415","author":"Siegling","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.autrev.2016.02.008_bb1250","series-title":"A primer of drug action: a concise, nontechnical guide to the actions, uses, and side effects of psychoactive drugs","first-page":"548","author":"Julien","year":"1997"},{"key":"10.1016\/j.autrev.2016.02.008_bb1255","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1155\/2001\/469629","article-title":"Medicinal use of cannabis: history and current status","volume":"6","author":"Kalant","year":"2001","journal-title":"Pain Res Manag"},{"key":"10.1016\/j.autrev.2016.02.008_bb1260","series-title":"Drogodependencias. Cannabis. Madri, Panamericana","first-page":"191","author":"Cerro","year":"1998"},{"key":"10.1016\/j.autrev.2016.02.008_bb1265","series-title":"Panorama atual de drogas e depend\u00eancias. 1\u00aa Ed., S\u00e3o Paulo, Atheneu","first-page":"361","author":"MacRae EJBN\u2014Redu\u00e7\u00e3o de Danos para o Uso da Cannabis","year":"2006"},{"key":"10.1016\/j.autrev.2016.02.008_bb1270","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","article-title":"Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression","volume":"23","author":"Moreira","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2016.02.008_bb1275","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1360-0443.1986.tb00358.x","article-title":"Cannabis psychosis","volume":"81","author":"Ghodse","year":"1986","journal-title":"Br J Addict"},{"key":"10.1016\/j.autrev.2016.02.008_bb1280","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/j.2051-5545.2008.tb00158.x","article-title":"Cannabis use and the risk of developing a psychotic disorder","volume":"7","author":"Hall","year":"2008","journal-title":"World Psychiatry"},{"key":"10.1016\/j.autrev.2016.02.008_bb1285","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/00007611-200408000-00022","article-title":"Marijuana-induced transient global amnesia","volume":"97","author":"Shukla","year":"2004","journal-title":"South Med J"},{"issue":"9","key":"10.1016\/j.autrev.2016.02.008_bb1290","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/npp.2014.67","article-title":"Long-term effects of cannabis on brain structure","volume":"39","author":"Battistella","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.autrev.2016.02.008_bb1295","first-page":"73","article-title":"Allergic rhinoconjunctivitis caused by Cannabis sativa pollen","volume":"18","author":"Mayoral","year":"2008","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.autrev.2016.02.008_bb1300","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-0536.2007.01169.x","article-title":"Work-related contact urticaria to Cannabis sativa","volume":"58","author":"Williams","year":"2008","journal-title":"Contact Dermatitis"},{"issue":"3","key":"10.1016\/j.autrev.2016.02.008_bb1305","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.psychres.2015.11.033","article-title":"Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis","volume":"230","author":"Buchy","year":"2015","journal-title":"Psychiatry Res"},{"issue":"2\u20134","key":"10.1016\/j.autrev.2016.02.008_bb1310","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cnr.2005.08.015","article-title":"Cannabis and endocannabinoid modulators: therapeutic promises and challenges","volume":"5","author":"Grant","year":"2005","journal-title":"Clin Neurosci Res"},{"key":"10.1016\/j.autrev.2016.02.008_bb1315","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1191\/0960327104ht426oa","article-title":"Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students","volume":"23","author":"El-Gohary","year":"2004","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.autrev.2016.02.008_bb1320","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1503\/cmaj.080585","article-title":"The adverse effects of cannabinoids: implications for use of medical marijuana","volume":"178","author":"Degenhardt","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.autrev.2016.02.008_bb1325","doi-asserted-by":"crossref","first-page":"99","DOI":"10.7861\/clinmedicine.8-1-99","article-title":"Recreational drug toxicity","volume":"8","author":"Hill","year":"2008","journal-title":"Clin Med"},{"key":"10.1016\/j.autrev.2016.02.008_bb1330","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.mce.2008.02.003","article-title":"Long lasting consequences of cannabis exposure in adolescence","volume":"286","author":"Rubino","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.autrev.2016.02.008_bb1335","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4081\/monaldi.2005.645","article-title":"Smoked marijuana as a cause of lung injury","volume":"63","author":"Tashkin","year":"2005","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1016\/j.autrev.2016.02.008_bb1340","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0165-5728(97)00228-2","article-title":"Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors","volume":"83","author":"Kaminski","year":"1998","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2016.02.008_bb1345","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0278-5846(85)90085-5","article-title":"Health consequences of acute and chronic marihuana use","volume":"9","author":"Maykut","year":"1985","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.autrev.2016.02.008_bb1350","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0167-5699(98)01300-0","article-title":"Cannabinoid receptors and immunity","volume":"19","author":"Klein","year":"1998","journal-title":"Immunol Today"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216300349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216300349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:04:25Z","timestamp":1752577465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997216300349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":270,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1568997216300349"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2016.02.008","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoids and autoimmune diseases: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2016.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}